EPIDEMIOLOGY AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC RENAL FAILIRE AND ANEMIA, RECEIVING PROGRAMM HEMODYALISISPart 2. Quality of life and costs of erythropoietin treatment
- Authors: Vorob'ev PA1, Bezmel'nitsyna LY.1
-
Affiliations:
- Issue: No 2 (2011)
- Pages: 45-48
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245965
- ID: 245965
Cite item
Full Text
Abstract
Aim. Assessment of life quality of patients with terminal renal failure an its dynamics during erythropoietin treatment.
Methods. Results of survey of 1395 patients with terminal renal failure and anemia, receiving program hemodyalisis, were analyzed.
Results. Most of the patients with terminal renal failure shows deterioration of life quality. Most of the erythropoietin medications can be used to achieve hemoglobin level >100 mmol/l; Eralfon is more effective, than Epocrin and helps to reduce treatment costs.
Conclusion. Erythropoietin medications can improve life quality and reduce treatment costs in patients with terminal renal failure
Methods. Results of survey of 1395 patients with terminal renal failure and anemia, receiving program hemodyalisis, were analyzed.
Results. Most of the patients with terminal renal failure shows deterioration of life quality. Most of the erythropoietin medications can be used to achieve hemoglobin level >100 mmol/l; Eralfon is more effective, than Epocrin and helps to reduce treatment costs.
Conclusion. Erythropoietin medications can improve life quality and reduce treatment costs in patients with terminal renal failure
References
- Weisbord S.D., Kimmel P.L. Health-related quality of life in the era of erythropoietin. Hemodial. Int. 2008; 12(1): 6-15
- Agarwal A.K., Singh A.K. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes. Heart Fail. Clin. 2010; 6(3): 323-332
- Evans R.W., Rader B., Manninen D.L. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. J.A.M.A. 1990; 263(6): 825-830
- Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. B.M.J. 1990; 300(6724): 573-578
- Foley R.N., Curtis B.M., Parfrey P.S. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin. J. Am. Soc. Nephrol. 2009; 4(4): 726-733
- Hynes D.M., Stroupe K.T., Greer J.W. et al. Potential cost savings of erythropoietin administration in end-stage renal disease. Am. J. Med. 2002; 112(3): 169-175
- Воробьев П.А., Безмельницына Л.Ю. Исследование эпидемиологии и качества жизни больных с анемией при хронической почечной недостаточности, находящихся на программном гемодиализе. Часть 1. Эпидемиологическая характеристика и особенности применения препаратов эритропоэтина. Клиническая нефрология. 2011; 1 (в печати)
Supplementary files
